<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Cytogenetic aberrations resulting in deletion of 3p are common in <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, indicating the presence of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor genes (TSG) on this chromosome arm </plain></SENT>
<SENT sid="1" pm="."><plain>The present study was undertaken to investigate 3p loss in <z:e sem="disease" ids="C1521860" disease_type="Disease or Syndrome" abbrv="">hematologic disorders</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Ten <z:hpo ids='HP_0004808'>acute myeloid leukemias</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>), two <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>), one <z:e sem="disease" ids="C0856536" disease_type="Neoplastic Process" abbrv="">Philadelphia chromosome-positive</z:e> <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (<z:mp ids='MP_0005481'>CML</z:mp>), three <z:hpo ids='HP_0006721'>acute lymphoblastic leukemias</z:hpo> (ALL), one <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005523'>lymphoproliferative disorder</z:hpo> (CLD), and three non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL) with abnormalities leading to 3p deletions were identified, constituting 2.9% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 0.7% of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 1.0% of <z:mp ids='MP_0005481'>CML</z:mp> with changes in addition to t(9;22), 1.5% of ALL, 4.2% of CLD, and 1.1% of NHL with cytogenetic abnormalities analyzed at our Department </plain></SENT>
<SENT sid="3" pm="."><plain>Among 19042 karyotypically aberrant published cases, 1.2% of 6260 AML, 1.3% of 2285 MDS, 0.8% of 840 <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0005547'>myeloproliferative disorders</z:hpo> (CMD), 0.7% of 1894 <z:mp ids='MP_0005481'>CML</z:mp> with additional aberrations to t(9;22), 0.6% of 3589 ALL 2.4% of 1602 CLD, 4.5% of 178 Hodgkin disease (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>), and 3.1% of 2394 NHL displayed partial loss of 3p (0.6-4.5%; P &lt; 0.001); the majority occurring together with other abnormalities </plain></SENT>
<SENT sid="4" pm="."><plain>The frequencies of 3p loss did not differ significantly among the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, ALL, and CLD morphologic subgroups, between B and T cell ALL, CLD, and NHL, among low-, intermediate-, and high-grade NHL, or between <z:e sem="disease" ids="C1292780" disease_type="Neoplastic Process" abbrv="">therapy-related MDS</z:e> and de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, whereas the incidence of 3p deletions was higher in treatment-associated <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (P &lt; 0.001) than in de novo <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and varied among the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> FAB groups (P &lt; 0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>The most frequently deleted chromosome bands were 3p25 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, 3p26 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>, 3p14 in CMD, 3p25, 3p23, and 3p21 in <z:mp ids='MP_0005481'>CML</z:mp>, 3p26 and 3p25 in ALL, 3p26 and 3p25 in CLD, 3p26 in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>, and 3p26 in NHL </plain></SENT>
<SENT sid="6" pm="."><plain>These deletion hot spots are more distal than those reported in most <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumor</z:e> types, suggesting that different TSG are involved in <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> and solid <z:hpo ids='HP_0002664'>neoplasms</z:hpo> </plain></SENT>
</text></document>